Jump to the top of the page

Investment Banking

The Quarterly Rx: Q3 2022 U.S. Biopharma Recap

While biopharma markets stabilized in Q3 2022—providing issuers with the most constructive financing environment we have seen year-to-date—macroeconomic issues remain the key headline risk for the near term. Key biopharma indices bounced off multiyear lows, driven by encouraging signs of M&A, meaningful positive clinical news, and broad sector short covering. William Blair's Biopharma team shares perspectives in “The Quarterly Rx: Q3 2022 U.S. Biopharma Recap.

Complete the form below to download your copy of the report.

Delivered to Your Inbox

Stay up-to-date with the latest William Blair news and insights

Subscribe to News Alerts

More News and Insights

  • Economics Weekly: The World Cup and Equity Markets

    In this Economics Weekly, we assess the economic impact of the World Cup on the host nations and consider how it fits into an increasingly competitive geopolitical backdrop.

    Read more

  • How Do War, Inflation, AI, and Portfolios All Connect?

    Geopolitical shocks and AI’s resource demands are adding new inflation pressure. Here’s what it means for asset allocation.

    Read more

  • Why the Roofing Industry Is the Next Frontier in Essential Services

    Like other parts of essential services—a broad category that covers everything from pool maintenance to landscaping—roofing has captured investors’ attention. The market is not only massive and fragmented but inherently non-discretionary, given the enduring need for functional roofs.

    Read more
See more insights

Are you sure you want to leave?

Information contained on the internet is not subject to William Blair & Company's control or review, and may not be accurate.

For disclosure information, please visit www.williamblair.com/disclosures